Emphasizes the importance of early diagnosis for a favourable outcome, covers the ever-increasing role of genetics in diagnosis and treatment, and discusses new and gold-standard treatments.

Multiple Myeloma accounts for approximately 0.8% of cancers worldwide, with about 114,000 new cases each year. Rapid progress is being made in the development of new treatments and, although myeloma is incurable at present, survival has almost tripled over the past 10 years and it is now projected that a third of patients will survive more than 10 years after diagnosis.

A chapter on supportive care also features and briefs the health care professional on long-term outcomes and quality of life issues. Primarily intended for primary care providers, specialist nurses, junior doctors and allied healthcare professionals, this highly readable resource provides a comprehensive overview of myeloma and other plasma cell dyscrasias, from bench to bedside, putting the pathogenesis, diagnosis and treatment of these disorders in the context of daily clinical practice.

Content covers:
- Epidemiology and etiology
- Predisposing conditions associated with myeloma
- Pathophysiology of myeloma and MGUS
- Diagnosis, staging and monitoring of myeloma
- Genetics and myeloma
- Induction therapy for newly diagnosed myeloma
- Transplantation and myeloma
- Relapsed and refractory myeloma
- Bone disease and renal complications in myeloma
- AL amyloidosis
- Rare plasma cell dyscrasias
- Supportive care
- Useful resources
Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias

Illustrations 23
Included In Health Press Fast Facts Book Collection 2019